2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in

NeoSci Ventures

Status
ACTIVE
Global HQ
Singapore
Countries of investment
  • Singapore
  • Taiwan
  • United States
Investment stages
  • Pre-Seed
  • Seed
Industries
  • Biotechnology
  • Life Sciences
  • Pharma
  • Biologics
  • Precision Medicine
  • Biology
  • AI
  • Data Science
  • Health Tech
  • Deep Tech
About
NeoSci Ventures, known as NSV, is a Singapore-based biotech venture builder and investor with operations in Singapore, Taiwan and the United States, founded by Daphne Teo, Timothy Lu and Jeffrey Lu, the team behind the NSG BioLabs co-working laboratory platform. In November 2026 it announced a $53M first close of its debut institutional venture fund, backed by EDBI, Taiwan's National Development Fund, Catcher Technology, Crescendas Group, family offices and entrepreneurs. The fund plans to build and back up to 12 companies worldwide in oncology, autoimmune and metabolic diseases and in tools combining biology, AI and data. It has made two investments so far, including NSV co-founded protein therapeutics company Protuoso Bio.
Min check size
$1M
Max check size
$4.4M
Fund size
NPS

Investment Thesis

NSV is a venture builder and investor that creates and funds biotech companies developing new therapies in oncology, autoimmune and metabolic diseases, as well as technologies at the intersection of biology, AI, data and scientific tools. It identifies the science, assembles scientific and management teams and builds companies from the earliest stage, with partners often taking founder, board or executive roles in the first years, including sourcing drug candidates from Asian biotech firms for pharma companies that need to refill pipelines. Its differentiation is a founder and scientist team with about 15 years of company building, 10 listings and acquisitions behind it, and the NSG BioLabs co-working lab platform, giving it deal flow and corporate partnerships across Singapore, Taiwan and the US.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Daphne Teo is the founder and CEO of NSV and NSG BioLabs, one of the largest co-working lab platforms in Singapore and Southeast Asia, after earlier roles at Goldman Sachs and HSBC. Timothy Lu was a tenured MIT faculty member from 2010 to 2022, co-founded and led Senti Bio, and co-founded or advised BiomX, Eligo Bioscience, Engine Biosciences, Synlogic and Tango Therapeutics. The founding team reports about 15 years of building and investing in biotech companies that raised billions of dollars and achieved 10 public listings and acquisitions, including Enleofen Bio, whose platform was acquired by Boehringer Ingelheim.

NeoSci Ventures Contacts Information

Primary contact

Secondary contact

Team

Daphne Teo - Founding Managing Partner

Timothy Lu - Founding Partner and Chief Scientist

Jeffrey Lu - Founding Partner

Darin Baur - CFO

Ken Nesmith - Venture Partner

Jamie Ng - Venture Partner

Fiona Lee - Assistant Vice President

Shih-Li Su - Assistant Vice President

Portfolio

Protuoso Bio

Fund number
Year Founded
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp